BRODSKY & SMITH INVESTOR ALERT: Updates on Ongoing Investigations into Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), and PotlatchDeltic Corporation (Nasdaq – PCH)
Sotherly Hotels Inc. Investigation: Brodsky & Smith is investigating whether the Sotherly Board breached its fiduciary duties by not ensuring a fair process in the acquisition by Kemmons Wilson Hospitality Partners and Ascendant Capital Partners, which offers $2.25 per share.
Hologic, Inc. Acquisition Scrutiny: The firm is looking into the Hologic Board's actions regarding its acquisition by Blackstone for $76 per share plus potential additional payments, assessing if shareholders are receiving fair value.
Astria Therapeutics, Inc. Merger Review: An investigation is underway concerning the Astria Board's fiduciary duties in the acquisition by BioCryst Pharmaceuticals, which values Astria shares at $13.00, to determine if a fair process was followed.
PotlatchDeltic Corporation Acquisition Inquiry: Brodsky & Smith is examining whether the PotlatchDeltic Board acted in the best interest of shareholders during its acquisition by Rayonier, which offers an exchange ratio implying a price of $44.11 per share.
Get Free Real-Time Notifications for Any Stock
Analyst Views on BCRX
About BCRX
About the author

Astria Therapeutics to be Sold to BioCryst for $8.55 per Share
- Transaction Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm are investigating the proposed sale of Astria Therapeutics to BioCryst Pharmaceuticals, which involves a compensation of $8.55 in cash and 0.59 shares of BioCryst stock per Astria share, aiming to assess whether this deal undervalues the company.
- Shareholder Rights Concern: KSF is seeking to confirm the adequacy of the transaction process and compensation, emphasizing the importance of protecting shareholder rights by inviting those who believe the deal undervalues the company to discuss their legal options.
- Legal Consultation Services: KSF offers no-obligation legal consultations, encouraging shareholders to contact Managing Partner Lewis S. Kahn, which highlights the firm's commitment to shareholder interests and the pursuit of transaction transparency.
- Market Reaction Potential: The investigation into this transaction could impact shareholder confidence and market performance for Astria, as any findings of unfairness may lead to legal actions that could subsequently affect the company's stock price trajectory.

BioCryst Grants 18,300 RSUs to New Employee as Inducement
- Employee Incentive Program: BioCryst granted 18,300 restricted stock units (RSUs) to a newly hired employee on January 2, 2026, as an inducement to attract and retain key talent essential for the company's growth.
- Vesting Terms: The RSUs will vest in four equal annual installments starting on the one-year anniversary of the grant date, ensuring the new employee's continued service, which enhances long-term commitment and stability within the workforce.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring transparency and adherence to regulations in the company's incentive measures, thereby boosting investor confidence.
- Company Background: BioCryst focuses on developing medicines for hereditary angioedema and other rare diseases, having successfully commercialized ORLADEYO®, the first oral, once-daily plasma kallikrein inhibitor, while advancing its innovative drug pipeline to meet market needs.








